Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
Immunotherapy biotech company Maxvax Biotechnology, based in Chengdu, has announced the successful closure of a...
Deals
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation
Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...
Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a...
Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
Shanghai Ark Biopharmaceutical Partners with Partex to Advance AI-Driven Drug Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has formed a strategic alliance with Germany-based Partex, an...
Zhongheng Group and Fosun Pharmaceutical Form JV to Boost Overseas Business
China-based Zhongheng Group (SHA: 600252) has announced plans to establish a joint venture (JV) with...
Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...
Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...
Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...